Competitive amplification of differentially melting amplicons (CADMA) enables sensitive and direct detection of all mutation types by high-resolution melting analysis

Human Mutation

Volumn 33, Issue 1, 2012, Pages 264-271

  Kristensen, Lasse S ^a   Andersen, Gitte B ^a   Hager, Henrik ^b   Hansen, Lise Lotte ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

CADMA; Cancer; COLD PCR; High resolution melting; HRM

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; PIK3CA PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ALLELE; AMPLICON; ARTICLE; COMPETITIVE AMPLIFICATION OF DIFFERENTIALLY MELTING AMPLICON; CONTROLLED STUDY; DNA DENATURATION; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; GENETIC PROCEDURES; HUMAN; HUMAN CELL; MELTING POINT; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TEMPERATURE; WILD TYPE;

ADENOCARCINOMA; BASE SEQUENCE; CELL LINE, TUMOR; COLONIC NEOPLASMS; DNA; DNA MUTATIONAL ANALYSIS; DNA PRIMERS; FREEZING; GENES, RAS; HOT TEMPERATURE; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; NUCLEIC ACID DENATURATION; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS B-RAF; SENSITIVITY AND SPECIFICITY; TRANSITION TEMPERATURE;

EID: 84857687561     PISSN: 10597794     EISSN: 10981004     Source Type: Journal    
DOI: 10.1002/humu.21598     Document Type: Article

References (29)

1. Amado RG, Wolf M, PeetersM, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD. 2008. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626-1634.
2. Cai Y, Yuan Y, Lin Q, Chan P. 2010. Allele-specific extension allows base-pair neutral homozygotes to be discriminated by high-resolution melting of small amplicons. Anal Biochem 406:29-33.
3. Germer S, Higuchi R. 1999. Single-tube genotyping without oligonucleotide probes. Genome Res 9:72-78.
4. Hansen LL, Andersen J, Overgaard J, Kruse TA. 1998. Molecular genetic analysis of easily accessible breast tumour DNA, purified from tissue left over from hormone receptor measurement. APMIS 106:371-377.
5. Jemal A, Siegel R, Xu J, Ward E. 2010. Cancer statistics, 2010. CA Cancer J Clin 60:277- 300.
6. Kobunai T, Watanabe T, Yamamoto Y, Eshima K. 2010. The frequency of KRAS mutation detection in human colon carcinoma is influenced by the sensitivity of assay methodology: a comparison between direct sequencing and real-time PCR. Biochem Biophys Res Commun 395:158-162.
7. Kristensen LS, Daugaard IL, Christensen M, Hamilton-Dutoit S, Hager H, Hansen LL. 2010. Increased sensitivity ofKRASmutation detection by high-resolutionmelting analysis of COLD-PCR products. Hum Mutat 31:1366-1373.
8. Kristensen LS, Hansen LL. 2009. PCR-based methods for detecting single-locus DNA methylation biomarkers in cancer diagnostics, prognostics, and response to treatment. Clin Chem 55:1471-1483.
9. Kristensen LS, Wojdacz TK, Thestrup BB, Wiuf C, Hager H, Hansen LL. 2009. Quality assessment of DNA derived from up to 30 years old formalin fixed paraffin embedded (FFPE) tissue for PCR-based methylation analysis using SMART-MSP and MS-HRM. BMC Cancer 9:453.
10. Kwok S, Chang SY, Sninsky JJ, Wang A. 1994. A guide to the design and use of mismatched and degenerate primers. PCR Methods Appl 3:S39-S47.
11. Lang AH, Drexel H, Geller-Rhomberg S, Stark N, Winder T, Geiger K, Muendlein A. 2011. Optimized allele-specific real-time PCR assays for the detection of common mutations in KRAS and BRAF. J Mol Diagn 13:23-28.
12. Li J, Berbeco R, Distel RJ, Janne PA, Wang L, Makrigiorgos GM. 2007. s-RT-MELT for rapid mutation scanning using enzymatic selection and real time DNA-melting: new potential for multiplex genetic analysis. Nucleic Acids Res 35:e84.
13. Li J, Milbury CA, Li C, Makrigiorgos GM. 2009a. Two-round coamplification at lower denaturation temperature-PCR (COLD-PCR)-based sanger sequencing identifies a novel spectrum of low-level mutations in lung adenocarcinoma. Hum Mutat 30:1583-1590.
14. Li J,Wang L,MamonH,KulkeMH, Berbeco R, Makrigiorgos GM. 2008. Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing. Nat Med 14:579-584.
15. Li J,Wang LL, Janne PA, Makrigiorgos GM. 2009b. Coamplification at lower denaturation temperature-PCR increases mutation-detection selectivity of TaqMan-based real-time PCR. Clin Chem 55:748-756.
16. Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Côté JF, Tomasic G, Penna C, DucreuxM, Rougier P, Penault-Llorca F, Laurent-Puig P. 2006. KRASmutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66:3992-3995.
17. Lievre A, Blons H, Laurent-Puig P. 2010. Oncogenic mutations as predictive factors in colorectal cancer. Oncogene 29:3033-3043.
18. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. 2004. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.N Engl J Med 350:2129-2139.
19. Milbury CA, Li J, Makrigiorgos GM. 2009a. COLD-PCR-enhanced high-resolution melting enables rapid and selective identification of low-level unknownmutations. Clin Chem 55:2130-2143.
20. Milbury CA, Li J,Makrigiorgos GM. 2009b. PCR-based methods for the enrichment of minority alleles and mutations. Clin Chem 55:632-640.
21. Milbury CA, Li J, Makrigiorgos GM. 2010. Ice-COLD-PCR enables rapid amplification and robust enrichment for low-abundance unknown DNA mutations. Nucleic Acids Res.
22. Montgomery JL, Sanford LN, Wittwer CT. 2010.High-resolutionDNA melting analysis in clinical research and diagnostics. Expert Rev Mol Diagn 10:219-240.
23. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. 2004. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497-1500.
24. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H. 2004. EGF receptor gene mutations are common in lung cancers from "never smokers"and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101:13306-13311.
25. Parsons BL, Heflich RH. 1997. Genotypic selection methods for the direct analysis of point mutations. Mutat Res 387:97-121.
26. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. 2002. Tumorigenesis: RAF/RAS oncogenes andmismatch-repair status. Nature 418:934.
27. Vogelstein B, Kinzler KW. 1999. Digital PCR. Proc Natl Acad Sci U S A 96:9236- 9241.
28. Whitehall V, Tran K, Umapathy A, Grieu F, Hewitt C, Evans TJ, Ismail T, Li WQ, Collins P, Ravetto P, Leggett B, Salto-Tellez M, Soong R, Fox S, Scott RJ, Dobrovic A, Iacopetta B. 2009. A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting. J Mol Diagn 11:543-552.
29. Wittwer CT. 2009. High-resolution DNA melting analysis: advancements and limitations. Hum Mutat 30:857-859.